Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir

Summary

Cytomegalovirus (CMV) is the most common opportunistic viral pathogen in solid organ transplant receptors (SOTR). In Mexico, the experience using generic immunosuppressants have been demonstrated a wide variation in the pharmacokinetic parameters between generic and innovative formulation, resulting in a suboptimal absorption of the drug and reaching infratherapeutic trough levels in blood. In this study the investigators will compare the pharmacokinetic parameters of innovative and generic valganciclovir in renal transplant recipients.

Timeline

Start

2018-03-01

Primary completion

2018-10-30

Completion

2018-11-01

Drugs

Indications